Browsing by Author "Serra, Violeta"

Sort by: Order: Results:

  • GDF15 is an eribulin response biomarker also required for survival of DTP breast cancer cells
    Bellio, Chiara; Emperador, Marta; Castellano, Pol; Gris-Oliver, Albert; Canals, Francesc; Sánchez Pla, Alexandre; Zamora¸ Esther; Arribas, Joaquín; Saura, Cristina; Serra, Violeta; Tabernero Cartula, Josep; Littlefield, Bruce A.; Villanueva, Josep (MDPI, 2022)
    Drug tolerant persister (DTP) cells enter into a reversible slow-cycling state after drug treatment. We performed proteomic characterization of the breast cancer (BC) DTP cell secretome after eribulin treatment. We showed ...
  • High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
    Palafox, Marta; Gonzalez-Perez, Abel; Arribas, Joaquín; López Bigas, Núria; Serra, Violeta (Nature Research, 2022)
    CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are ...
  • Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
    Mateo, Lidia; Duran-Frigola, Miquel, 1985-; Gris-Oliver, Albert; Palafox, Marta; Scaltriti, Maurizio; Razavi, Pedram; Chandarlapaty, Sarat; Arribas, Joaquín; Bellet, Meritxell; Serra, Violeta; Aloy, Patrick, 1972- (BioMed Central, 2020)
    Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence ...